Zomanex Overview

  • Founded
  • 2006

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Investors
  • 1

Zomanex General Information

Description

Operator of a drug formulation development company intended to transform intravenous, injectable and oral therapeutics into novel orally delivered medicines. The company's products help in the conversion of intravenous or injectable xenobiotics into orally deliverable substances, as well as make it easy for hydrophobic compounds to be absorbed in the small intestine, enabling physicians to permit oral dosing of pharmaceutical compounds that have previously been administered intravenously or by injection.

Contact Information

Website
www.zomanex.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Drug Delivery
Primary Office
  • Suite 2600 Three Bentall Centre
  • Post Office Box 49314, 595 Burrard Street
  • Vancouver, British Columbia V7X 1L3
  • Canada
+1 (604) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zomanex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC (Series A) 12-Oct-2017 Completed Generating Revenue
To view Zomanex’s complete valuation and funding history, request access »

Zomanex Patents

Zomanex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2008309010-B2 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Inactive 28-Sep-2007 0000000000 0
AU-2008309010-A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007 0000000000
CA-2701023-C Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007 0000000000
CA-2701023-A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007 0000000000
EP-2205219-A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007 A61K31/337
To view Zomanex’s complete patent history, request access »

Zomanex Executive Team (3)

Name Title Board Seat Contact Info
Paul Drohan Chief Executive Officer
Curtis Spilburg Ph.D Chief Scientific Officer
Doris Schnelle Director, Business Development
To view Zomanex’s complete executive team members history, request access »

Zomanex Board Members (1)

Name Representing Role Since
Peter Craddock Shoreline Venture Management Board Member 000 0000
To view Zomanex’s complete board members history, request access »

Zomanex Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Shoreline Venture Management Venture Capital Minority 000 0000 000000 0
To view Zomanex’s complete investors history, request access »